Literature DB >> 22647741

Long-term prognosis of an endoscopically treated rectal neuroendocrine tumor: 10-year experience in a single institution.

Hye Young Sung1, Sang Woo Kim, Won Kyung Kang, Su Young Kim, Chan-Kwon Jung, Yu Kyung Cho, Jae Myung Park, In Seok Lee, Myung-Gyu Choi, In-Sik Chung.   

Abstract

BACKGROUND AND AIM: The endoscopic techniques for treating a small rectal neuroendocrine tumor (NET) are performed in most large centers; however, the endoscopic management of this condition is not well established. This study was designed to determine the long-term prognosis of endoscopically resected NET.
METHODS: We prospectively studied patients with endoscopically treated rectal NET in Seoul St Mary's hospital, between January 2000 and June 2010. The long-term outcomes were analyzed in association with the pathological complete resection and resection procedures.
RESULTS: Seventy-seven patients (48 men and 29 women; mean age, 52.3 years; range, 23-77 years) were included. The average NET size was 7.0±2.8 mm (range, 3-16 mm). There was no procedure-related complication. En-bloc removal was achieved for all lesions, and the rate of histological complete resection was 75.3% (58/77). Histological complete resection rates were 71.4% (10/14) by conventional endoscopic mucosal resection (EMR), 74.1% (43/58) by a two-channel EMR, and 100.0% (5/5) by endoscopic submucosal dissection (ESD). Among six patients with incomplete histological resection, two underwent additional EMR, two underwent transanal endoscopic microsurgery, and two underwent low anterior section with lymph node dissection. The remaining 13 patients with 'possible' remnant NET underwent regular endoscopic surveillance without additional resection. In the latter group, only one patient had local recurrence, detected on regular colonoscopic surveillance, after 56 months and was treated with additional EMR. All of the patients are alive and 98.7% (76/77) of the patients are free from disease during the follow-up periods.
CONCLUSION: Endoscopic resection is a safe and effective modality and may potentially be used for the treatment of NETs smaller than 15 mm in diameter, those confined to the submucosal layer, and those without metastasis. Local treatment was believed to be curative in cases with complete histological resection. In addition, this treatment may have an excellent prognosis in patients with 'possible' remnant NET.

Entities:  

Mesh:

Year:  2012        PMID: 22647741     DOI: 10.1097/MEG.0b013e3283551e0b

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  21 in total

Review 1.  Which endoscopic treatment is the best for small rectal carcinoid tumors?

Authors:  Hyun Ho Choi; Jin Su Kim; Dae Young Cheung; Young-Seok Cho
Journal:  World J Gastrointest Endosc       Date:  2013-10-16

2.  Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Authors:  Hong Shen; Zhuo Yu; Jing Zhao; Xiu-Zhen Li; Wen-Sheng Pan
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

3.  Prognosis of rectal neuroendocrine tumors after endoscopic resection: a single-center retrospective study.

Authors:  Yue Zheng; Kehang Guo; Ruijie Zeng; Zhendao Chen; Wanwei Liu; Xiaoguang Zhang; Weimin Liang; Jianhua Liu; Hao Chen; Weihong Sha
Journal:  J Gastrointest Oncol       Date:  2021-12

4.  Prognosis of incompletely resected small rectal neuroendocrine tumor using endoscope without additional treatment.

Authors:  Boram Cha; Jongbeom Shin; Weon Jin Ko; Kye Sook Kwon; Hyungkil Kim
Journal:  BMC Gastroenterol       Date:  2022-06-09       Impact factor: 2.847

5.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

6.  Transanal endoscopic microsurgery as optimal option in treatment of rare rectal lesions: A single centre experience.

Authors:  Monica Ortenzi; Roberto Ghiselli; Maria Michela Cappelletti Trombettoni; Luca Cardinali; Mario Guerrieri
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

7.  Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study.

Authors:  Chang Mo Moon; Kyu Chan Huh; Sung-Ae Jung; Dong Il Park; Won Hee Kim; Hye Mi Jung; Seong-Joon Koh; Jin-Oh Kim; Yunho Jung; Kyeong Ok Kim; Jong Wook Kim; Dong-Hoon Yang; Jeong Eun Shin; Sung Jae Shin; Eun Soo Kim; Young-Eun Joo
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

8.  Endoscopic submucosal resection with an endoscopic variceal ligation device for the treatment of rectal neuroendocrine tumors.

Authors:  Masahide Ebi; Shoko Nakagawa; Yoshiharu Yamaguchi; Yasuhiro Tamura; Shinya Izawa; Yasutaka Hijikata; Takaya Shimura; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Takashi Joh; Kunio Kasugai
Journal:  Int J Colorectal Dis       Date:  2018-08-30       Impact factor: 2.571

Review 9.  Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs).

Authors:  Francesco Maione; Alessia Chini; Marco Milone; Nicola Gennarelli; Michele Manigrasso; Rosa Maione; Gianluca Cassese; Gianluca Pagano; Francesca Paola Tropeano; Gaetano Luglio; Giovanni Domenico De Palma
Journal:  Diagnostics (Basel)       Date:  2021-04-25

10.  A case of rectal neuroendocrine tumor presenting as polyp.

Authors:  Halil Rakici; Remzi Adnan Akdogan; Cüneyt Yurdakul; Neşe Canturk
Journal:  Int J Surg Case Rep       Date:  2015-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.